A 43-year-old man died from drug toxicity just one day after receiving prescriptions for temazepam and pregabalin via telehealth while already hospitalized for a drug-related infection, a coroner has found. The case highlights the potential risks associated with prescribing practices, particularly when patients have a history of substance use and are receiving care for related conditions. The incident raises critical questions about the coordination of care and the appropriateness of telehealth prescriptions in vulnerable populations.
The man, who had a documented history of prescription drug misuse and reported using methamphetamine approximately once a week, was admitted to hospital for an infection stemming from intravenous drug use, alongside a concurrent COVID-19 diagnosis. Despite being an inpatient, he received additional prescriptions from three general practitioners at his regular clinic in the days leading up to his death in April 2023. This allowed him to obtain a 18-day supply of pregabalin the day before he died.
The Dangerous Combination of Medications
The coroner’s findings center on the inappropriate prescribing of temazepam and pregabalin, two medications that, when combined, can significantly increase the risk of adverse effects. Drugs.com details that using these medications together can amplify side effects such as dizziness, drowsiness, confusion and difficulty concentrating. These effects are particularly pronounced in elderly individuals, but can affect anyone, potentially impairing thinking, judgment, and motor coordination.
Pregabalin, sold under the brand name Lyrica, is typically prescribed for nerve pain, fibromyalgia, and certain types of seizures. Temazepam, marketed as Restoril, is a benzodiazepine commonly used to treat insomnia. Benzodiazepines, as a class of drugs, are central nervous system depressants, meaning they slow down brain activity. Combining them with other depressants, like pregabalin, creates an additive effect, increasing the risk of respiratory depression, and overdose.
Understanding the Risks of Additive CNS Depression
According to HelloPharmacist, the concurrent use of pregabalin and central nervous system depressants like temazepam can lead to respiratory depression, a potentially life-threatening condition where breathing becomes dangerously shallow or stops altogether. This risk is heightened in patients with pre-existing lung conditions, such as chronic obstructive pulmonary disease (COPD), and in older adults.
The FDA Adverse Event Reporting System (FAERS) database, cited by HelloPharmacist, documented 49 cases of respiratory depression associated with gabapentinoids (including pregabalin) between January 2012 and October 2017. A respiratory risk factor, such as age or concurrent use of a CNS depressant, was present in 92% of these cases. Twelve deaths occurred, and all of those deaths involved at least one respiratory risk factor.
Telehealth and the Challenges of Patient Monitoring
The case also brings into focus the challenges of providing care through telehealth, particularly when a patient has complex medical needs and a history of substance use. While telehealth offers increased access to care, it can also make it more difficult for physicians to fully assess a patient’s condition and monitor for potential adverse effects. The coroner’s report suggests that the telehealth consultations did not adequately account for the patient’s existing vulnerabilities and the potential for dangerous drug interactions.
The man’s ability to fill an 18-day prescription for pregabalin while hospitalized underscores a potential gap in communication and coordination between the hospital and his primary care physicians. It raises questions about whether the GPs were fully aware of his hospitalization and the medications he was already receiving.
The Importance of Comprehensive Medication Review
Experts emphasize the importance of a comprehensive medication review for all patients, but especially those with a history of substance use or those receiving multiple prescriptions. This review should include a thorough assessment of all medications, including over-the-counter drugs and supplements, to identify potential drug interactions and ensure that the benefits of each medication outweigh the risks.
Initiating pregabalin at the lowest effective dose and closely monitoring patients for signs of respiratory depression and sedation are crucial steps in mitigating the risks associated with this medication, particularly when used in combination with other CNS depressants.
This case serves as a stark reminder of the potential consequences of inappropriate prescribing practices and the demand for greater vigilance in protecting vulnerable patients. Further investigation into the prescribing practices of the three GPs involved is ongoing, and the coroner’s report will likely prompt a review of telehealth protocols and medication safety measures within the healthcare system.
The next step in this case is a review of the coroner’s recommendations by the relevant medical boards and healthcare authorities. This review will likely lead to changes in prescribing guidelines and telehealth protocols aimed at preventing similar tragedies in the future. Readers are encouraged to share their thoughts and experiences with telehealth and medication safety in the comments below.
Related reading
